Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
about
The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory DiseasesOral Apremilast for the Treatment of Plaque PsoriasisSelective Phosphodiesterase 4B Inhibitors: A ReviewThalidomide-a notorious sedative to a wonder anticancer drug.Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma.Small Molecules in the Treatment of Psoriasis.A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma.Advances in treating psoriasis.Novel investigational therapies for atopic dermatitis.New treatments for inflammatory rheumatic disease.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.Apremilast for the treatment of psoriasis.Apremilast for the treatment of psoriatic arthritis.A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Nonribosomal peptides and polyketides of Burkholderia: new compounds potentially implicated in biocontrol and pharmaceuticals.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1[Guidelines for vaccination of immunocompromised individuals].Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosumApremilast in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Study.Next-generation antipsoriatic drugs: small molecules join.Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways.East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.
P2860
Q26750377-BCE345C0-3E10-4D0E-828A-DEBE0E7E2980Q28075724-4A810D73-B4B7-4E17-9EF9-52BFC88079B2Q28081071-2BA6478C-5636-431C-B488-F5C9FEFCCF15Q33956871-39B4CDB7-0FEA-430F-BEA1-92C1678016A2Q35062625-CE4CA595-9B59-4767-9EC3-3AAFEA5222F3Q35740706-C5921670-917B-4FA9-AE16-0B09A5DFAC27Q35937121-1C0BF2BD-6452-40E9-9CBF-DD2362DE8764Q36061710-E7609887-BB44-42C1-9487-068F64C863EEQ37104915-97D8775C-8C91-4A30-90DA-CA912FFBB2B4Q38104404-37DB35B2-C304-4F23-9E46-47E7C11C5879Q38193099-D923E9C5-2488-4718-A301-D1693E5A07F1Q38247119-3BFEBD46-F920-47A4-B82C-4929E81EE987Q38266252-CB9007CA-47E9-4E81-9CD4-24E8376EFC31Q38416536-F63A447B-99A2-43C9-809F-5976A94026C8Q38543069-95331176-E668-4C25-968B-80609EFF6DF8Q38561061-CD188FBA-077C-4D06-B603-3873963A8553Q38616811-BE5C7014-B49E-4A74-BB3D-BFFD646D95A7Q38675867-0E2C1B06-670F-47C8-A5C1-8E434EC1854BQ38762222-000B96E6-2478-414B-B2B4-1FA2E6B3DC6CQ38766379-6F9203BA-F973-49B4-9741-F5AE7C7F47E2Q38885459-9D68AAE5-1DEA-48AD-BC6F-99D849B0A162Q39375417-9E72CACD-4BAF-47D9-9279-7FF498C0FF0EQ40204659-DB75962B-69C7-417D-8365-9F8DDD183A5CQ40600058-159C9B84-4EE7-4077-9059-F9374629FDCEQ41540546-B2ABD026-E132-49B5-B577-0E33E7383FE8Q42291222-5CA25156-BE0D-4D0F-9648-9E9CC0FAA7D1Q48225472-107493D5-4599-487C-A603-76DBFC8CF7F3Q48273986-1DA4D914-2601-4258-BC08-BAE61C8F9C36Q50117437-44D9C68B-C360-4451-807C-6FF94D346688Q51733163-86237803-A5DE-4FF0-9DB6-BCFD2B48E399Q51772071-D7AAD684-9199-493C-BBB1-36FFB5E88850
P2860
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.
@en
type
label
Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.
@en
prefLabel
Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.
@en
P2093
P2860
P356
P1476
Apremilast: a novel PDE4 inhib ...... une and inflammatory diseases.
@en
P2093
Peter Schafer
Randall M Stevens
Victor S Sloan
P2860
P304
P356
10.1177/1759720X10381432
P50
P577
2010-10-01T00:00:00Z